Why Is ZYMEWORKS INC (ZYME) Stock Up Today?

ZYME stock rose 5.35% to $28.94 in early trading on August 26, driven by a series of analyst upgrades and regulatory developments tied to its partnership with Jazz Pharmaceuticals. The FDA approved Jazz’s Ziihera-based regimens for the treatment of advanced HER2-positive gastroesophageal cancer, triggering a $250 million milestone payment to Zymeworks. Multiple analysts have since raised their price targets, with H.C. Wainwright increasing its target to $55 and Citi raising its to $38.

What Happened

The stock’s move followed the FDA’s approval of Jazz Pharmaceuticals’ Ziihera regimens, which was announced on August 25. Zymeworks, as a partner in the development of the therapy, received a significant milestone payment. The company filed an 8-K with the SEC to disclose the event under Regulation FD. Analysts responded quickly, with H.C. Wainwright raising its price target from $51 to $55 and Citi from $37 to $38. Citizens also reiterated its Market Outperform rating with a $32 price target. These developments contributed to a surge in early morning trading, with the stock hitting a session high of $29.00.

What The Data Shows

The stock opened at $27.53 and traded as low as $27.00 before recovering. Trading volume reached 0.1 million shares, which is 0.2 times the 3-month daily average. Over the last 8 sessions, ZYME has risen 7.0%, from $24.96 to $26.71. The stock closed the session at $28.94, near its session high. On August 26, ZYME printed seven fresh 52-week highs, indicating strong short-term momentum. Retail traders on r/wallstreetbets discussed the FDA decision and whether the move was already priced in.

What To Watch

Zymeworks does not have an upcoming earnings date, but coverage breadth will be an important factor to monitor. Analysts have shown a recent increase in optimism, and the stock’s performance could continue to reflect developments in its partnership with Jazz Pharmaceuticals.